尼可刹米治疗急性期慢性阻塞性肺疾病合并呼吸衰竭的疗效分析

Efficacy analysis of nikethamide in the treatment of acute chronic obstructive pulmonary disease with respiratory failure

目的探讨尼可刹米治疗急性期慢性阻塞性肺疾病(COPD)合并呼吸衰竭的临床疗效。方法80例慢性阻塞性肺疾病合并呼吸衰竭患者,随机分为对照组与观察组,各40例。对照组患者使用小剂量甲基强的松龙治疗,观察组患者在对照组基础上使用尼可刹米治疗。比较两组临床疗效及治疗前后血气功能指标、肺功能指标。结果观察组治疗总有效率为90.0%,显著高于对照组的72.5%,差异有统计学意义(P<0.05)。治疗前,两组心率、动脉血氧分压、动脉血二氧化碳分压及第1秒用力呼气容积占预计值的百分比(FEV1%)、第1秒用力呼气容积占用力肺活量百分比(FEV1/FVC)水平比较,差异无统计学意义(P>0.05);治疗后,两组心率、动脉血氧分压、动脉血二氧化碳分压、FEV1%及FEV1/FVC均优于治疗前,且观察组心率(83.4±8.3)次/min、动脉血氧分压(81.5±7.5)mm Hg(1 mm Hg=0.133 kPa)、动脉血二氧化碳分压(51.4±7.9)mm Hg、FEV1%(71.5±6.5)%及FEV1/FVC(78.3±8.7)%均优于对照组的(90.5±6.0)次/min、(77.7±6.5)mm Hg、(61.2±10.1)mm Hg、(68.1±6.2)%、(66.9±7.3)%,差异有统计学意义(P<0.05)。结论应用尼可刹米治疗急性期慢性阻塞性肺疾病合并呼吸衰竭能显著提高临床疗效,改善呼吸衰竭症状,改善生活质量,值得临床推广。

Objective To discuss the clinical efficacy of nikethamide in the treatment of acute chronic obstructive pulmonary disease(COPD)with respiratory failure.Methods A total of 80 patients with chronic obstructive pulmonary disease and respiratory failure were randomly divided into control group and observation group,with 40 cases in each group.Patients in the control group were treated with low-dose methylprednisolone,and patients in the observation group were treated with nikethamide on the basis of the control group.The clinical efficacy,blood gas function indexes and pulmonary function indexes before and after treatment were compared between the two groups.Results The total effective rate of treatment in the observation group was 90.0%,which was significantly higher than 72.5%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no statistically significant differences between the two groups in terms of heart rate,arterial partial pressure of oxygen,arterial partial pressure of carbon dioxide,and forced expiratory volume in the 1st second as a percentage of the predicted value(FEV1%)and FEV1/forced vital capacity as a percentage of the predicted value(FEV1/FVC)(P>0.05).After treatment,the heart rate,arterial partial pressure of oxygen,arterial partial pressure of carbon dioxide,FEV1%and FEV1/FVC in both groups were better than those before treatment;the heart rate(83.4±8.3)beats/min,arterial partial pressure of oxygen(81.5±7.5)mm Hg(1 mm Hg=0.133 kPa),arterial partial pressure of carbon dioxide(51.4±7.9)mm Hg,FEV1%(71.5±6.5)%and FEV1/FVC(78.3±8.7)%in the observation group were better than(90.5±6.0)beats/min,(77.7±6.5)mm Hg,(61.2±10.1)mm Hg,(68.1±6.2)%,and(66.9±7.3)%in the control group;all the differences were statistically significant(P<0.05).Conclusion Nikethamide can significantly improve the clinical efficacy of patients with chronic obstructive pulmonary disease and respiratory failure,improve the symptoms of respiratory failure,and improve the quality of life,which is worthy of clinical promotion.